Compound for increasing kinase active and application thereof

1. A compound of Formula (I), or pharmaceutically acceptable salts thereof,

wherein:

W and Y are each C;

X is O;

Z is C;

R 1 is selected from the group consisting of —H, alkanyl, substituted alkanyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, C(═O)R 5 , SR 5 , SO 2 R 5 and haloalkyl; R 5 is selected from the group consisting of C 1-6 alkanyl, substituted C 1-6 alkanyl, alkoxy, substituted alkoxy and NR 6 R 7 ; R 6 and R 7 are independently selected from the group consisting of —H, C 1-6 alkanyl, and substituted C 1-6 alkanyl, or R 6 and R 7 can join together to form a 3 to 6 membered ring or a substituted 3 to 6 membered ring;

R 2 is selected from the group consisting of —H, alkanyl, substituted alkanyl, halogen and haloalkyl;

R 3 is selected from the group consisting of substituted alkanyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl and substituted heterocycloalkyl; and

R 4 is selected from the group consisting of heteroaryl and substituted heteroaryl, wherein at least one ortho atom of the heteroaryl connected with NH in Formula (I) is N.

2. The compound of claim 1 , wherein R 1 is selected from the group consisting of C(═O)R 5 , SRS, SO 2 R 5 and haloalkyl; and wherein R 5 is selected the group consisting of C 1-3 alkanyl, substituted C 1-3 alkanyl, NR 6 R 7 , C 1-6 alkoxy, and substituted C 1-6 alkoxy.

3. The compound of claim 1 , wherein R 2 is —H; wherein R 3 is selected from the group consisting of cycloalkanyl, substituted cycloalkanyl, heterocycloalkyl and substituted heterocycloalkyl; and wherein R 4 is substituted 5- or 6-membered heteroaryl.

4. The compound of claim 2 , wherein R 3 is

5. The compound of claim 3 , wherein R 1 is SO 2 R 5 ; R 5 is C 1-3 alkanyl.

6. The compound of claim 1 , wherein R 3 is

7. The compound of claim 1 , wherein the compound is selected from the group consisting of:

ethyl 6-(4-(4-(4-(methylsulfonyl)phenoxy)-3-((3-oxocyclopentyl)methyl)phenylamino) nicotinate;

3-(2-(4-(methylsulfonyl)phenoxy)-5-(5-methylthiazol-2-ylamino)benzyl)cyclopentanone;

3-(2-(4-(methylsulfonyl)phenoxy)-5-(pyrazin-2-ylamino)benzyl)cyclopentanone;

3-(5-(3-methyl-1,2,4-thiadiazol-5-ylamino)-2-(4-(methylsulfonyl) phenoxy)benzyl)cyclopentanone;

3-(5-(1H-imidazol-4-ylamino)-2-(4-(methylsulfonyl)phenoxy)benzyl)cyclopentanone;

3-(2-(4-(methylsulfonyl)phenoxy)-5-(5-(trifluoromethyl)pyridin-2-ylamino)benzyl)cyclopentanone;

ethyl 6-(4-(4-(methylsulfonyl)phenoxy)-3-((tetrahydro-2H-pyran-4-yl)methyl)phenylamino)nicotinate;

N-(4-(4-(methylsulfonyl)phenoxy)-3-((tetrahydro-2H-pyran-4-yl)methyl)phenyl)-5-(trifluoromethyl)pyridin-2-amine;

N-(4-(4-(methylsulfonyl)phenoxy)-3-((tetrahydro-2H-pyran-4-yl)methyl)phenyl) pyrazin-2-amine;

3-methyl-N-(4-(4-(methylsulfonyl)phenoxy)-3-((tetrahydro-2H-pyran-4-yl)methyl)phenyl)-1,2,4-thiadiazol-5-amine;

N-(4-(4-(methylsulfonyl)phenoxy)-3-((tetrahydro-2H-pyran-4-yl)methyl)phenyl)-1H-imidazol-4-amine;

5-methyl-N-(4-(4-(methylsulfonyl)phenoxy)-3-((tetrahydro-2H-pyran-4-yl)methyl)phenyl)thiazol-2-amine;

ethyl 6-(3-((1-acetylpyrrolidin-2-yl)methyl)-4-(4-(methylsulfonyl) phenoxy)phenylamino)nicotinate;

1-(2-(2-(4-(methylsulfonyl)phenoxy)-5-(5-(trifluoromethyl)pyridin-2-ylamino)benzyl) pyrrolidin-1-yl)ethanone;

1-(2-(2-(4-(methylsulfonyl)phenoxy)-5-(pyrazin-2-ylamino)benzyl)pyrrolidin-1-yl) ethanone;

1-(2-(5-(3-methyl-1,2,4-thiadiazol-5-ylamino)-2-(4-(methylsulfonyl) phenoxy)benzyl) pyrrolidin-1-yl)ethanone;

1-(2-(5-(1H-imidazol-4-ylamino)-2-(4-(methylsulfonyl) phenoxy)benzyl)pyrrolidin-1-yl)ethanone;

1-(2-(2-(4-(methylsulfonyl)phenoxy)-5-(5-methylthiazol-2-ylamino)benzyl)pyrrolidin-1-yl)ethanone;

ethyl 6-(4-(4-dimethylcarbamoyl)phenoxy)-3-((3-oxocyclopentyl)methyl)phenylamino)nicotinate;

N,N-dimethyl-4-(4-(5-methylthiazol-2-ylamino)-2-((3-oxocyclopentyl)methylphenoxy)benzamide;

N,N-dimethyl-4-(2-((3-oxocyclopentyl)methyl)-4-(pyrazin-2-ylamino) phenoxy)benzamide;

N,N-dimethyl-4-(4-(3-methyl-1,2,4-thiadiazol-5-ylamino)-2-((3-oxocyclopentyl)methyl)phenoxy)benzamide;

4-(4-(1H-imidazol-4-ylamino)-2-((3-oxocyclopentyl)methyl)phenoxy)-N,N-dimethylbenzamide;

N,N-dimethyl-4-(2-((3-oxocyclopentyl)methyl)-4-(5-(trifluoromethyl)pyridin-2-ylamino)phenoxy)benzamide;

6-(4-(4-(dimethylcarbamoyl)phenoxy)-3-((tetrahydro-2H-pyran-4-yl)methyl)phenyl amino)nicotinic acid;

N,N-dimethyl-4-(2-((tetrahydro-2H-pyran-4-yl)methyl)-4-(5-(trifluoromethyl)pyridin-2-ylamino)phenoxy)benzamide;

N,N-dimethyl-4-(4-(pyrazin-2-ylamino)-2-((tetrahydro-2H-pyran-4-yl)methyl) phenoxy)benzamide;

N,N-dimethyl-4-(4-(3-methyl-1,2,4-thiadiazol-5-ylamino)-2-((tetrahydro-2H-pyran-4-yl)methyl)phenoxy)benzamide;

4-(4-(1H-imidazol-4-ylamino)-2-((tetrahydro-2H-pyran-4-yl)methyl)phenoxy)-N,N-dimethylbenzamide;

N,N-dimethyl-4-(4-(5-methylthiazol-2-ylamino)-2-((tetrahydro-2H-pyran-4-yl)methyl) phenoxy)benzamide;

6-(3-((1-acetylpyrrolidin-2-yl)methyl)-4-(4-(dimethylcarbamoyl) phenoxy)phenyl amino)nicotinic acid;

4-(2-((1-acetylpyrrolidin-2-yl)methyl)-4-(5-(trifluoromethyl)pyridin-2-ylamino) phenoxy)-N,N-dimethylbenzamide;

4-(2-((1-acetylpyrrolidin-2-yl)methyl)-4-(pyrazin-2-ylamino)phenoxy)-N,N-dimethylbenzamide;

2-(6-(4-(4-(4-(dimethylcarbamoyl)phenoxy) 3-((tetrahydro-2H-pyran-4-yl)methyl)phenylamino)pyridin-3-yl)acetic acid;

3-(6-(4-(4-(dimethylcarbamoyl)phenoxy)-3-((tetrahydro-2H-pyran-4-yl)methyl)phenylamino)pyridin-3-yl)propanoic acid;

2-(6-(3-((1-acetylpyrrolidin-2-yl)methyl)-4-(4-(dimethylcarbarnoyl) phenoxy)phenylamino)pyridin-3-yl)acetic acid; or

3-(6-(3-((1-acetylpyrrolidin-2-yl)methyl)-4-(4-(dimethylcarbamoyl)phenoxy)phenylamino)pyridin-3-yl)propanoic acid.

8. A method of modulating glucokinase levels or activities in animals or humans by administering to the subject at least one compound of claim 1 .

9. A method for treating and/or preventing type II diabetes or related disease thereof, by administering to the subject a therapeutically effective amount of the compound of claim 1 .

10. A method for treating and/or preventing type I diabetes or related disease thereof, by administering to the subject a therapeutically effective amount of the compound of claim 1 .

11. A method for treating and/or preventing obesity or related disease thereof, by administering to the subject a therapeutically effective amount of the compound of claim 1 .

12. The compound of claim 5 , wherein R 4 is substituted 5 or 6 membered heteroaryl, and wherein one substitution is C 1-3 carboxylate.

13. The compound of claim 6 , wherein R 4 is selected from the group consisting of 5-membered heteroaryl, 6-membered heteroaryl, substituted 5-heteroaryl and 6-membered heteroaryl.

14. The compound of claim 13 , wherein R 4 is selected from the group consisting of

15. The compound of claim 14 , wherein R is selected from the group consisting of lower alkanyl, C 1-6 alkoxy, C(═O)R 5 and SO 2 R 5 , wherein R 5 is selected from the group consisting of lower alkanyl and NR 6 R 7 , and wherein R 6 and R 7 are independently selected from the group consisting of —H and lower alkanyl, or R 6 and R 7 can join together to form a 3 to 6 membered ring.

16. The compound of claim 15 , wherein R 2 is —H, or halogen.

17. The compound of claim 16 , wherein R 3 is

and wherein R 4 is selected from the group consisting of

18. The compound of claim 16 , wherein R is —H; wherein R 1 is C(═O)NR 6 R 7 or SO 2 R 5 ; and wherein R 5 is C 1-3 alkanyl.

19. A pharmaceutical composition, comprising a therapeutically effective amount of at least one compound of claim 1 , and at least one pharmaceutically acceptable excipient, adjuvant or carrier.

20. A pharmaceutical composition, comprising a therapeutically effective amount of at least one compound of claim 7 , and at least one pharmaceutically acceptable excipient, adjuvant or carrier.

21. A method of modulating glucokinase levels or activities in animals or humans by administering to the subject at least one compound of claim 7 .

22. A method for treating and/or preventing type II diabetes or related disease thereof, by administering to the subject a therapeutically effective amount of the compound of claim 7 .

23. A method for treating and/or preventing type I diabetes or related disease thereof, by administering to the subject a therapeutically effective amount of the compound of claim 7 .

24. A method for treating and/or preventing obesity or related disease thereof, by administering to the subject a therapeutically effective amount of the compound of claim 7 .